Positioning of Glucocorticosteroids in Asthma and Allergic Rhinitis Guidelines (Versus Other Therapies) - 18/08/11

Doi : 10.1016/j.iac.2005.06.001

Guy F. Joos, MD, PhD ^a,⁎ , Guy G. Brusselle, MD, PhD ^a, Helen Van Hoecke, MD ^b, Paul Van Cauwenberge, MD, PhD ^b, Jean Bousquet, MD, PhD ^c, Romain A. Pauwels, MD, PhD ^{^{✠
Deceased January 3, 2005.}}
^a Department of Respiratory Diseases, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium
^b Department of Oto-rhino-laryngology, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium
^c Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier, France

^*Corresponding author

Résumé

Asthma and allergic rhinitis are both characterized by airway inflammation, and glucocorticosteroids form the cornerstone of their pharmacologic treatment. All patients with asthma should be prescribed rapid-acting inhaled β₂-agonists as needed to use as rescue therapy in case of symptoms. As soon as patients experience symptoms at least once a week, controller medications should be started on a daily basis to achieve and maintain control of their asthma. Intranasal corticosteroids are given as first-line therapy for moderate to severe persistent rhinitis. Depending on the dominant symptom, H₁-antihistamines, decongestants, or ipratropium can be added after re-evaluation.

Le texte complet de cet article est disponible en PDF.